Ultragenyx’s 'high-risk' Angelman bet fails, cratering stock and forcing strategic review
Phase 3negativeapazunersenNegative
AI Analysis
Summary
Ultragenyx's apazunersen failed its Phase 3 trial for Angelman syndrome, a critical asset for the company's pipeline and valuation. The failure has triggered stock decline and forced a strategic review of the company's direction.
Clinical Trial Data
Phase
3
Primary Endpoint
Not Met
Outcome Details
Phase 3 trial failure for apazunersen in Angelman syndrome
Importance:9/10
Sentiment:
-0.95
Phase 3 failureAngelman syndromestock declinestrategic reviewclinical setback
Related Companies
Read the original article
Published by BioSpace on September 3, 2026 11:38 AM